Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) have earned a consensus rating of “Hold” from the seven analysts that are covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $8.71.
A number of equities analysts recently commented on CCCC shares. Wells Fargo & Company raised their target price on C4 Therapeutics from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Thursday, May 9th. Stifel Nicolaus increased their target price on shares of C4 Therapeutics from $13.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, May 9th.
Read Our Latest Report on C4 Therapeutics
Institutional Inflows and Outflows
C4 Therapeutics Stock Up 0.9 %
Shares of C4 Therapeutics stock opened at $6.50 on Tuesday. C4 Therapeutics has a twelve month low of $1.06 and a twelve month high of $11.88. The company has a market cap of $447.27 million, a price-to-earnings ratio of -2.74 and a beta of 3.07. The company’s 50 day moving average is $5.17 and its 200 day moving average is $6.68.
C4 Therapeutics (NASDAQ:CCCC – Get Free Report) last posted its earnings results on Wednesday, May 8th. The company reported ($0.41) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.41). The company had revenue of $3.04 million for the quarter, compared to the consensus estimate of $10.93 million. C4 Therapeutics had a negative return on equity of 52.85% and a negative net margin of 629.24%. Sell-side analysts expect that C4 Therapeutics will post -1.56 EPS for the current fiscal year.
C4 Therapeutics Company Profile
C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.
Recommended Stories
- Five stocks we like better than C4 Therapeutics
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Why Call Options Volume for These 2 Stocks Spiked Together
- Stock Splits, Do They Really Impact Investors?
- MarketBeat Week in Review – 7/22 – 7/26
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.